Category Archives: Best mode

Eurand et al. (“Cephalon”) v. Mylan Pharmaceuticals, Inc. et al.

Docket No. 2011-1399, -1409 NEWMAN, O’MALLEY, REYNA April 16, 2012 Subject matter: ANDA/generics, obviousness Brief summary: Bioequivalence parameters are not necessarily obvious, and “therapeutically effective” claims may prove very valuable. Best mode may not be found where there is enablement. … Continue reading

Posted in Best mode, Generics / ANDA, Obviousness | Leave a comment